Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
34.03
-0.08 (-0.23%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
3
4
5
Next >
Genentech to Present New Pivotal Data at ASH 2021 From Broad and Comprehensive Portfolio, Challenging Treatment Standards for People With Blood Disorders
November 23, 2021
From
Genentech
Via
Business Wire
FDA Approves Genentech’s Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet Age-Related Macular Degeneration (AMD)
October 22, 2021
From
Genentech
Via
Business Wire
FDA Approves Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer
October 15, 2021
From
Genentech
Via
Business Wire
NetworkNewsAudio – Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Harnessing Power of Real-World Data
October 14, 2021
Via
Investor Brand Network
New 4-Year Data Show Genentech’s Enspryng (satralizumab-mwge) Significantly Reduces Debilitating Relapses in People With Neuromyelitis Optica Spectrum Disorder
October 14, 2021
From
Genentech
Via
Business Wire
New Data up to 8-Years for Genentech’s Ocrevus (ocrelizumab) Show Early and Ongoing Treatment Significantly Reduced Risk of Requiring a Walking Aid in Relapsing Multiple Sclerosis and Disability Progression in Primary Progressive Multiple Sclerosis
October 13, 2021
From
Genentech
Via
Business Wire
Real-World Data, Point-of-Care Testing Reshaping Healthcare, Detecting Diseases Sooner
October 12, 2021
Via
Investor Brand Network
Genentech’s Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer’s Disease
October 08, 2021
From
Genentech
Via
Business Wire
Ad hoc announcement pursuant to Art. 53 LR: Genentech’s Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer’s Disease
October 08, 2021
From
Genentech
Via
Business Wire
Genentech to Present New Data on Ocrevus (ocrelizumab) in Multiple Sclerosis and Enspryng (satralizumab-mwge) in Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2021
October 05, 2021
From
Genentech
Via
Business Wire
New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space
September 20, 2021
Via
FinancialNewsMedia
New Phase III Data Support the Benefit of Genentech’s Tecentriq in Early-stage Lung Cancer
September 20, 2021
From
Genentech
Via
Business Wire
Genentech to Present Data From Industry-Leading Portfolio at ESMO 2021 Showing Significant Progress in Early Stage and Uncommon Cancers
September 07, 2021
From
Genentech
Via
Business Wire
Genentech Provides Update on Tecentriq U.S. Indication for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
August 27, 2021
From
Genentech
Via
Business Wire
Phase III Study Shows Genentech's Polivy Plus R-CHP Is the First Regimen in 20 Years to Significantly Improve Outcomes in Previously Untreated Aggressive Form of Lymphoma Compared to Standard of Care
August 09, 2021
From
Genentech
Via
Business Wire
FDA Grants Priority Review to Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-small Cell Lung Cancer
August 03, 2021
From
Genentech
Via
Business Wire
FDA Accepts Application for Genentech’s Faricimab for the Treatment of Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)
July 29, 2021
From
Genentech
Via
Business Wire
Data for Genentech’s Evrysdi (risdiplam) Published in New England Journal of Medicine Shows Significant Improvement in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
July 28, 2021
From
Genentech
Via
Business Wire
FDA Grants Breakthrough Therapy Designation for Venclexta in Combination With Azacitidine for the Treatment of Patients With Myelodysplastic Syndromes
July 21, 2021
From
Genentech
Via
Business Wire
New Data for Genentech’s Hemlibra (emicizumab-kxwh) Reinforce Safety Profile in People With Hemophilia A
July 19, 2021
From
Genentech
Via
Business Wire
Genentech’s Actemra Receives FDA Emergency Use Authorization for the Treatment of COVID-19 In Hospitalized Adults and Children
June 24, 2021
From
Genentech
Via
Business Wire
FDA Accepts Application for Genentech’s Port Delivery System With Ranibizumab (PDS) for Treatment of Wet Age-Related Macular Degeneration (AMD)
June 24, 2021
From
Genentech
Via
Business Wire
Genentech Announces Data at EHA2021 Reinforcing Efficacy of Venclexta Combinations in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
June 11, 2021
From
Genentech
Via
Business Wire
New Genentech Data for Evrysdi (risdiplam) Show Improved Motor Function in Pre-Symptomatic Babies After One Year and Confirm Safety Profile in Previously Treated People With Spinal Muscular Atrophy (SMA)
June 11, 2021
From
Genentech
Via
Business Wire
Genentech Presents Latest Advances With Immunotherapies in Non-Hodgkin’s Lymphoma
June 04, 2021
From
Genentech
Via
Business Wire
Pivotal Phase III Data at ASCO Show Genentech’s Tecentriq Helps Certain People With Early Lung Cancer Live Significantly Longer Without Their Disease Returning
May 19, 2021
From
Genentech
Via
Business Wire
Genentech to Present Data From One of the Most Comprehensive Oncology Portfolios at the 2021 ASCO Annual Meeting Showcasing Advancements for People Living With Cancer
May 11, 2021
From
Genentech
Via
Business Wire
Biotechs Zero in on Growing Ovarian Cancer Market as Pivotal Trials Advance Through Regulatory Agencies
May 03, 2021
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
FDA Advisory Committee Votes in Favor of Maintaining Accelerated Approval of Genentech’s Tecentriq for Previously Untreated Metastatic Bladder Cancer
April 28, 2021
From
Genentech
Via
Business Wire
FDA Advisory Committee Votes in Favor of Maintaining Accelerated Approval of Genentech’s Tecentriq for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
April 27, 2021
From
Genentech
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.